Clinically Significant
Kancure’s pipelines focus on the unmet medical needs in treating brain tumors
Innovative Ideas
Kancure designed compounds that can cross blood brain barrier for brain tumors treatment
Drug the ‘Undruggable’
Kancure’s technology can downregulate traditionally undruggable proteins
About us
Targeted Protein Degradation
Even with comprehensive treatment—including surgery, radiation, and chemotherapy—glioblastoma often recurs. The typical recurrence rate approaches nearly 100% within 6-12 months after initial treatment for most patients. This is due to the highly infiltrative nature of the tumor and its resistance to conventional therapies.
Kancure focus on using targeted protein degradation (TPD) that leverages the cell’s natural protein disposal system to selectively degrade disease-causing or malfunctioning proteins in brain tumor. Unlike traditional drugs that typically inhibit the function of a target protein, TPD leads to its complete destruction. This approach has shown promise in treating cancers, neurodegenerative diseases, and other conditions caused by problematic proteins..
Brain Cancer
The blood-brain barrier, a protective layer that regulates what enters the brain, makes it difficult for many chemotherapy drugs to reach the brain tumor.
Glioblastoma
Glioblastoma has a poor prognosis, with a median survival time of 12-18 months despite aggressive treatment. Fewer than 10% of patients survive five years post-diagnosis. The disease often recurs after initial treatment due to its highly aggressive nature, making ongoing research critical for developing more effective therapies.
Brain Metastasis
Brain metastasis is the most common form of brain cancer, with metastatic tumors being much more prevalent than primary brain tumors. The most common primary cancers that metastasize to the brain are lung cancer, breast cancer, melanoma, renal cell carcinoma (kidney cancer), and colorectal cancer.
Diffuse Intrinsic Pontine Glioma
Diffuse Intrinsic Pontine Glioma (DIPG) is a rare and highly aggressive brainstem tumor that primarily affects children, usually between the ages of 5 and 10. This cancer develops in the pons, a part of the brainstem, making it exceptionally difficult to treat due to its critical location and infiltrative nature.
Radiotherapy
Radiotherapy is a key treatment for brain tumors
Radiation therapy is a key treatment option for many types of brain tumors. It uses high-energy beams, such as X-rays, protons, or other particles, to target and destroy cancer cells. Radiation therapy may be used as a primary treatment, after surgery to kill any remaining cancer cells, or to help relieve symptoms if the tumor cannot be surgically removed.
Protein Degradation
TPD eliminates the target protein from the cell, which can be beneficial for proteins that are difficult to inhibit through traditional binding sites
PROTACs (PROteolysis Targeting Chimeras) are an innovative class of small molecules designed to induce the selective degradation of disease-causing proteins within cells. By leveraging the body’s natural protein degradation machinery, PROTACs offer a unique approach to targeting proteins that have traditionally been considered “undruggable.” This emerging therapeutic strategy has gained significant attention for its potential in treating cancers, neurodegenerative diseases, and other conditions. Kancure is leading PROTACs that can degrade critical protein essential for brain tumor progression.
Our team
Shuhua (Steve) Zheng, DO, PhD
Co-founder
Yilin Wu, PhD
co-founder
Mengying Sun, AICPA
Financial manager
“In nature, nothing is created, nothing is lost, everything changes.” – Antoine Lavoisier
Our Pipelines
Kancre is preclinical stage biotechnology company creating novel compounds for GBM, brain metastasis, DIPG and neurodegenerative diseases treatment
